By utilizing DNA as a functional organic material, we are developing a “DNA linker technology” that enables precise conjugation of antibodies with drugs and functional molecules, alongside related applications such as cell adhesion and enzyme-free nucleic acid detection. Our unique molecular design enhances the performance and multifunctionality of diverse materials, establishing foundational technologies for ADC drug development, 3D cell models, and diagnostic platforms. Furthermore, we expand these technologies into research support and collaborative R&D to accelerate industrial application and societal implementation.
Drug development for neurodegenerative diseases.
A startup developing mass-producible platelet preparations using technology to generate platelets from human iPS cells. It aims to provide stable supplies to medical settings in developed and developing countries facing blood donation shortages, thereby supporting transfusion medicine.
Aortic stenosis is a life-threatening condition in which the aortic valve becomes severely narrowed. With an aging population, the number of patients is expected to increase dramatically worldwide in the coming years. Although valve replacement has become widely adopted, many patients are either too frail to tolerate the procedure or lack access to specialized treatment centers. As a result, a significant treatment gap still remains. DIVE, the device we are developing, synchronizes balloon expansion with the heartbeat to gently open the narrowed aortic valve. Its key advantage is the minimal physical burden on the patient. Through this technology, we aim to provide a safe and accessible treatment option — and ultimately save as many lives as possible.
A startup advancing drug discovery through proprietary platform technology that selectively delivers drugs to immune cells, both through in-house development and collaborative partnerships. It aims to create novel therapies for intractable diseases by controlling immune responses.